Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05932901 · ClinicalTrials.gov registry record
OPTIMISE-CKD Drug Utilization
A clinical trial, sponsored by AstraZeneca.
- Completed
- Registry status
- 2,682,052
- Enrollment target
NCT05932901 is a clinical trial that has completed, run by AstraZeneca. The registered enrollment target is 2,682,052 participants.
The verdict
NCT05932901 has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- 2,682,052 participants
- Enrollment target
Study Summary
This is a multi-national, observational study program using secondary data sources to address research questions related to 1) real-world dapagliflozin utilisation in CKD and potential for further utilisation, 2), the current CKD treatment landscape and 3) real-world effectiveness of dapagliflozin in CKD (pending feasibility assessment).
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,682,052 participants |
| Start Date | 2022-05-04 |
| Est. Completion | 2023-09-28 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05932901
The ClinicalTrials.gov registry entry for NCT05932901 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 2,682,052 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT05932901 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05932901 about?
NCT05932901 is a clinical study titled "OPTIMISE-CKD Drug Utilization". This is a multi-national, observational study program using secondary data sources to address research questions related to 1) real-world dapagliflozin utilisation in CKD and potential for further utilisation, 2), the current CKD treatment landscape and 3) real-world effectiveness of dapagliflozin i...
What is the current status of trial NCT05932901?
This trial is currently completed. The enrollment target is 2,682,052 participants. The study started on 2022-05-04. Estimated completion is 2023-09-28.
Who is sponsoring clinical trial NCT05932901?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.